#United States #New York #Securities #Pomerantz #Ultragenyx

Pomerantz Law Firm Investigates Ultragenyx Pharmaceutical Inc.

On August 6, 2025, the Pomerantz Law Firm announced an investigation into potential claims on behalf of investors holding shares in Ultragenyx Pharmaceutical Inc., trading under the ticker symbol RARE on NASDAQ. The firm is looking into whether the company and certain executive officers may have participated in securities fraud or engaged in other improper business practices that could have harmed investors.

The alert follows a significant drop in Ultragenyx's stock price after the company, in partnership with Mereo BioPharma Group plc, reported developments regarding their Phase 3 clinical trial for UX143, known as setrusumab, which aims to treat osteogenesis imperfecta (OI) in children and young adults. On July 9, 2025, Ultragenyx issued a press release detailing the progress of the trial and stated that the final analysis would take place around the end of the year. However, this announcement led to a drastic decline in stock value, with prices plunging by $10.41, or 25.11%, closing at $31.04 per share the next day.

The purpose of Pomerantz's investigation is to ascertain whether the executives at Ultragenyx made false or misleading statements regarding the status of their clinical trials, which could indicate deeper management issues within the firm. Investors who believe they may have been misled are encouraged to reach out to Pomerantz for further information on how to participate in the class action.

Pomerantz LLP, established over 80 years ago, is recognized as a leader in the realm of corporate, securities, and antitrust litigation. The firm, founded by the esteemed Abraham L. Pomerantz, continues the legacy of fighting for victims of corporate misconduct and securities fraud. The firm’s efforts have secured numerous substantial damage awards for victims, reinforcing their reputation as a robust advocate for investors' rights.

As the market adjusts to this development, stakeholders in Ultragenyx should remain vigilant and informed. This situation underscores the importance of transparency and accountability within pharmaceutical companies, especially when investors are affected. Shareholders who wish to be part of this legal action may contact Danielle Peyton at Pomerantz LLP for more details and guidance on the claims process.

To learn more about the Pomerantz Law Firm and ongoing investigations, visit their website at www.pomerantzlaw.com. Please note that past performance does not guarantee future results, and all potential investors should make informed decisions based on comprehensive research.

Investors are advised to proceed with caution, staying aware of developments to protect their investments during this tumultuous time. Whether you're a long-term holder or a more recent investor, it’s crucial to understand how corporate governance and the accuracy of communications impact stock prices and overall market trust.